TTOO vs. LYRA, STIM, KRMD, BLUA, BWAY, SRTS, HSAQ, ALUR, PDEX, and NVNO
Should you be buying T2 Biosystems stock or one of its competitors? The main competitors of T2 Biosystems include Lyra Therapeutics (LYRA), Neuronetics (STIM), KORU Medical Systems (KRMD), BlueRiver Acquisition (BLUA), BrainsWay (BWAY), Sensus Healthcare (SRTS), Health Sciences Acquisitions Co. 2 (HSAQ), Allurion Technologies (ALUR), Pro-Dex (PDEX), and enVVeno Medical (NVNO). These companies are all part of the "surgical & medical instruments" industry.
Lyra Therapeutics (NASDAQ:LYRA) and T2 Biosystems (NASDAQ:TTOO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, community ranking, dividends, analyst recommendations, institutional ownership, earnings and risk.
Lyra Therapeutics currently has a consensus target price of $7.13, suggesting a potential upside of 2,036.43%. T2 Biosystems has a consensus target price of $3.00, suggesting a potential downside of 40.71%. Given T2 Biosystems' higher possible upside, equities analysts clearly believe Lyra Therapeutics is more favorable than T2 Biosystems.
95.6% of Lyra Therapeutics shares are held by institutional investors. Comparatively, 23.2% of T2 Biosystems shares are held by institutional investors. 17.4% of Lyra Therapeutics shares are held by company insiders. Comparatively, 0.1% of T2 Biosystems shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Lyra Therapeutics has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500. Comparatively, T2 Biosystems has a beta of 0.05, suggesting that its share price is 95% less volatile than the S&P 500.
T2 Biosystems has a net margin of -636.09% compared to T2 Biosystems' net margin of -4,099.82%. Lyra Therapeutics' return on equity of 0.00% beat T2 Biosystems' return on equity.
In the previous week, T2 Biosystems had 1 more articles in the media than Lyra Therapeutics. MarketBeat recorded 5 mentions for T2 Biosystems and 4 mentions for Lyra Therapeutics. Lyra Therapeutics' average media sentiment score of 0.87 beat T2 Biosystems' score of 0.15 indicating that T2 Biosystems is being referred to more favorably in the news media.
T2 Biosystems has higher revenue and earnings than Lyra Therapeutics.
T2 Biosystems received 384 more outperform votes than Lyra Therapeutics when rated by MarketBeat users. Likewise, 64.65% of users gave T2 Biosystems an outperform vote while only 61.11% of users gave Lyra Therapeutics an outperform vote.
Summary
T2 Biosystems beats Lyra Therapeutics on 8 of the 15 factors compared between the two stocks.
Get T2 Biosystems News Delivered to You Automatically
Sign up to receive the latest news and ratings for TTOO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TTOO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
T2 Biosystems Competitors List
Related Companies and Tools
